<DOC>
	<DOCNO>NCT00008073</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Octreotide may help doxorubicin kill cancer cell make tumor cell sensitive drug . PURPOSE : Phase I trial study effectiveness octreotide doxorubicin treat patient advanced cancer .</brief_summary>
	<brief_title>Octreotide Doxorubicin Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity maximum tolerate dose octreotide administer doxorubicin patient advance cancer . II . Determine pharmacokinetics pharmacodynamics treatment regimen patient . OUTLINE : This dose escalation study octreotide . Patients receive doxorubicin IV 5 minute day 1 course 1 . For subsequent course , patient receive octreotide SC continuously day 1-7 doxorubicin IV 5 minute day 5 . Treatment continue every 3 week absence disease progression unacceptable toxicity . Patients stable responsive disease 3 course therapy receive maximum 6 additional course . Cohorts 3-6 patient receive escalate dos octreotide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : Approximately 21-30 patient accrue study .</detailed_description>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignancy ineligible therapy proven great benefit doxorubicin alone Measurable evaluable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 mg/dL SGOT great 4 time normal Renal : Creatinine great 2 mg/dL Cardiovascular : LVEF least 50 % No compensate uncompensated congestive heart failure Other : Not pregnant Fertile patient must use effective contraception 2 month study No history gallstone gallbladder place PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy ( 6 week mitomycin nitrosourea ) recover No 240 mg/m2 total cumulative dose prior doxorubicin Endocrine therapy : Prior octreotide allow Recovered prior octreotide Radiotherapy : At least 3 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>